Cancer Network spoke with Dr. Shulin Li about his team's research on the role of the FGL2 protein in glioblastoma immune evasion and tumor progression.
In this study, single-agent ofatumumab did not show superiority to rituximab or obinutuzumab, raising the question of whether ofatumumab should have a role in the treatment of follicular lymphoma.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: UBM Medica, a divsion of UBM Americas
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
